Sign in

    Joshua Korsen

    Managing Director and Senior Equity Research Analyst at H.C. Wainwright

    Joshua Korsen is a Managing Director and Senior Equity Research Analyst at H.C. Wainwright, specializing in biotechnology and life sciences sectors with a focus on small- to mid-cap companies. He actively covers firms such as Chimerix, Mustang Bio, and Nektar Therapeutics, demonstrating a strong record of insightful analysis and actionable investment recommendations that have garnered a success rate above 60% and delivered notable average returns per TipRanks analyst rankings. Korsen began his professional career in equity research over a decade ago, previously holding research and analyst positions at LifeSci Capital and Sidoti & Company prior to joining H.C. Wainwright in 2020. He holds FINRA Series 7, 63, 86, and 87 licenses, supporting his credibility as a respected analyst in the equity research industry.

    Joshua Korsen's questions to Panbela Therapeutics (PBLA) leadership

    Joshua Korsen's questions to Panbela Therapeutics (PBLA) leadership • Q1 2024

    Question

    Inquired about the company's current cash position, plans to strengthen the balance sheet, and clarification on the components of the reported cash balance from Q1.

    Answer

    The company's cash burn is increasing to nearly $7 million per quarter. They filed an S-1 and plan to raise more capital upon uplisting to a national exchange. The reported Q1 cash balance included proceeds from a January offering but did not include a subsequent payment received in April.

    Ask Fintool Equity Research AI